The discovery that BRAF and NRAS mutations are two of the main oncogenic drivers of melanoma proliferation and survival has resulted in important therapeutic implications and changed the management of cutaneous melanoma patients with the development of specific targeted therapies based on MAPK pathway inhibitors [12]. The gene discussed is BRAF; the disease is melanoma.